---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011845"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:28:14.305289+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences advances PMN310 to final dose cohort in Alzheimer's Phase 1b trial

## Summary
- DSMB unanimously recommends proceeding to third and final dose escalation cohort (20 mg/kg) after safety review.
- Cohort 2 fully enrolled; no cases of amyloid-related imaging abnormalities (ARIA) observed to date.
- Enrollment of Cohort 3 underway; 6-month interim data expected Q2 2026, final top-line results Q4 2026.
- Trial to enroll 128 patients with comprehensive biomarker panel including pTau217, NfL, GFAP, and synaptic markers.
- PMN310 holds FDA Fast Track designation; CEO to present at H.C. Wainwright conference on Sept 10, 2025.

## SEC filing metadata
- accession: 0001558370-25-011845
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/0001558370-25-011845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/pmn-20250903x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011845
- JSON: https://secwatch.observer/filing/0001558370-25-011845.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.